DUBLIN, Dec. 18, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/mqs7t3/merger_and) has announced the addition of the "Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics" report to their offering.
The Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all merger and acquisition deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Key Topics Covered:
2. Trends in M&A dealmaking
2.2. Difference between merger and acquisition deals
2.3. Trends in M&A deals since 2009
2.4. When M&A can be useful
2.5. Attributes of M&A deals
2.6. Partnering deals with M&A component
2.7. Bigpharma mega mergers - are we at the end of the road?
2.8. Accessing innovation through M&A
2.9. The emerging role of private equity in M&A
2.10. Implementing M&A transactions
2.11. Joint ventures as alternative to M&A
2.12. The future of M&A in biopharma
3. Overview of M&A deal structure
3.2. Pure versus multi-component acquisition deals
3.3. Pure M&A agreement structure
3.4. Acquisition as part of a wider alliance agreement
3.5. Merger agreements
4. Leading M&A deals
4.2. Top M&A deals by value
4.3. Top merger deals
4.4. Bigpharma M&A deal activity
5. Bigpharma M&A deals
5.2. How to use M&A deals
5.3. Bigpharma company M&A deal profiles
6. M&A contracts directory
6.2. Company A-Z
6.3. By industry sector
For more information visit http://www.researchandmarkets.com/research/mqs7t3/merger_and
Laura Wood , +353-1-481-1716, firstname.lastname@example.org
|SOURCE Research and Markets|
Copyright©2012 PR Newswire.
All rights reserved